TransMedics Group (NASDAQ:TMDX) Given New $85.00 Price Target at JPMorgan Chase & Co.

TransMedics Group (NASDAQ:TMDX) had its target price upped by analysts at JPMorgan Chase & Co. from $73.00 to $85.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential downside of 3.67% from the stock’s current price.

TMDX has been the topic of several other research reports. Barclays initiated coverage on TransMedics Group in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price on the stock. Needham & Company LLC upped their price target on TransMedics Group from $106.00 to $110.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. UBS Group dropped their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Finally, TD Cowen reissued a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a report on Tuesday, September 8th. Five analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $112.20.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $88.24 on Friday. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.53 and a quick ratio of 4.15. The firm has a market capitalization of $3.05 billion, a PE ratio of 23.91, a price-to-earnings-growth ratio of 1.18 and a beta of 2.14. The business’s fifty day moving average price is $79.61 and its 200 day moving average price is $93.17.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.30 by $0.21. The company had revenue of $203.01 million during the quarter, compared to the consensus estimate of $178.06 million. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. TransMedics Group’s revenue for the quarter was up 41.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.66 EPS. On average, sell-side analysts anticipate that TransMedics Group will post 1.50 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, Director David Weill acquired 1,336 shares of the company’s stock in a transaction on Friday, September 11th. The shares were bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the completion of the acquisition, the director owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 6.90% of the stock is owned by corporate insiders.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Pinnacle Wealth Planning Services Inc. grew its stake in TransMedics Group by 24.9% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 874 shares of the company’s stock worth $73,000 after buying an additional 174 shares during the last quarter. Plan A Wealth LLC lifted its stake in TransMedics Group by 3.9% in the third quarter. Plan A Wealth LLC now owns 5,370 shares of the company’s stock valued at $448,000 after buying an additional 203 shares during the last quarter. IFP Advisors Inc lifted its stake in TransMedics Group by 4.8% in the second quarter. IFP Advisors Inc now owns 4,652 shares of the company’s stock valued at $309,000 after buying an additional 213 shares during the last quarter. HB Wealth Management LLC boosted its holdings in shares of TransMedics Group by 1.5% in the second quarter. HB Wealth Management LLC now owns 15,062 shares of the company’s stock valued at $1,000,000 after acquiring an additional 219 shares during the period. Finally, D.A. Davidson & CO. boosted its holdings in shares of TransMedics Group by 1.4% in the third quarter. D.A. Davidson & CO. now owns 16,060 shares of the company’s stock valued at $1,340,000 after acquiring an additional 228 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services.

The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.